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FOLFIRI. CONCLUSIONS: FOLFOX appears to have favorable cost effectiveness 
compared to other agents in the treatment of stage IV colorectal cancer, even after 
factoring in the impact of generic irinotecan.
PODIUM SESSION I: DRUG UTILIZATION STUDIES
DU1
PHYSICAL FUNCTION AND THE CONCOMITANT USE OF
ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE 
INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA
Modi A1, Craig B1, Weiner M2, Sands L1, Thomas J1
1Purdue University, West Lafayette, IN, USA, 2Indiana University, Indiana University Center for 
Aging Research and Regenstrief Institute Inc, Indianapolis, IN, USA
OBJECTIVES: Antihistamines with anticholinergic properties (AA) are often used to
treat comorbidities in patients with dementia. Use of AA with cholinesterase inhibitors 
(CHI) may counteract beneﬁ ts of CHI in improving activities of daily living (ADL) or 
slowing ADL decline. Associations between use of AA with CHI and ADL function 
were assessed. METHODS: A retrospective cohort analysis of Indiana Medicaid 
claims and enrollment data from July 2001 through December 2005 merged with 
Minimum Data Set (MDS) identiﬁ ed persons q65 years, with dementia based on previ-
ously assessed criteria for identifying dementia and, receiving CHI. Persons taking 
anticholinergics other than AA during the study interval from ﬁ rst to last MDS assess-
ment during CHI use were excluded. Piecewise repeated measures analysis used days 
taking AA and days not taking AA during each assessment interval as predictors to
estimate inﬂ uence of AA use on MDS ADL function scores (range 0–28, higher scores 
 more dependence). Presence of shifts in curves and changes in slopes deﬁ ned changes 
in ADL. Age, gender, race, region, marital status and number of medications taken at 
the start of CHI use, Charlson comorbidity score and propensity score for receipt of 
AA were included as ﬁ xed covariates. RESULTS: A sample of 2,690 persons with 
mean age of 82 years, 75% female and, 90% white was identiﬁ ed. Of these, 691 
(26%) used AA. Overall, a 0.45 (p  0.02) upward shift in ADL score indicated an
immediate decrease in ADL function with AA use. Among persons with moderate 
ADL dependence (score 6–12), an increase in slope of 0.53 (p  0.04) per quarter also
was observed indicating faster decline with AA use. CONCLUSIONS: Use of AA with 
CHI is associated with greater ADL decline in Medicaid recipients with dementia. 
Potential impact of AA use on physical function should be considered before prescrib-
ing AA with CHI.
DU2
RACIAL DIAPARITIES AND BARRIER TO DRUG UTILIZATION IN
PATIENTS WITH DIABETES IN THE UNITED STATES
Seetasith A, Zhang JX
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: We sought to assess barriers to the appropriate statin usage measured
through out-of-pocket payment by insurance status and racial disparities in patients 
with diabetes. METHODS: We analyzed 1,708 civilian, non-institutionalized patients 
with diabetes aged between 20 and 85 in the 2003 Medical Expenditure Panel 
survey (MEPS), a nationally representative survey in the United States which was 
linked to drug utilization ﬁ les. We categorized patients with diabetes into six mutually
exclusive insurance groups. We performed bivariate chi-square tests to assess the 
association between race and statins use, and insurance status and statin use during 
the year. We further performed multivariate logistic regression analysis to assess the 
effect of race/ethnicity on statin usage for patients of different races/ethnicity, control-
ling for socioeconomic variables, and co-morbid conditions. RESULTS: Among the 
population, 369 (21.6%) were African American, 66 (3.9%) Asian and 396 (23.2%)
were Hispanic; the mean out-of-pocket payment per prescription of statins was $61.4
(SD $62.5) for Medicare patients, $24.0 (SD $43.7) for Medicaid patients, $ 25.4 (SD
$49.0) for patients with dual eligibility, $35.2 (SD $33.5) for those with private insur-
ance, $76.7 (SD $47.8) for those without insurance, and $83.9 (SD $90.5) for others. 
In bivariate analysis, statin usage was found to be signiﬁ cantly different across races 
and insurance status (p  0.020 and p  0.0001, respectively). In multivariate regres-
sion analysis, compared to White patients, African American patients were less likely 
to use statin (adjusted OR 0.57, 95% CI 0.43–0.76, p  0.0001). Asian and Hispanic 
patients were marginally less likely to use statin (adjusted OR 0.60, 95% CI 0.34–
1.05, p  0.078; and adjusted OR 0.75, 95% CI 0.56–1.00, p  0.055, respectively). 
CONCLUSIONS: Drug utilization is associated with insurance coverage. Racial/eth-
nicity disparity is observed in drug utilization of patients with diabetes after adjusting 
for insurance status.
DU3
PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH
CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE
ANALYSIS OF ADMINISTRATIVE CLAIMS DATA
Vekeman F1, Laliberte F1, Afonja O2, Lafeuille MH1, Barghout V2, Duh MS3, Skarin AT4
1Groupe d’analyse, Ltee, Montréal, QC, Canada, 2Bayer HealthCare Pharmaceuticals, Inc, 
Wayne, NJ, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Dana-Farber Cancer Institute, 
Boston, MA, USA
OBJECTIVES: Pegﬁ lgrastim is a long-acting granulocyte colony-stimulating factor 
(G-CSF) used to prevent or treat febrile neutropenia associated with myelosuppressive
anticancer therapies. According to the prescribing information, pegﬁ lgrastim should
not be administered within 14 days before or 24 hours after cytotoxic chemotherapy 
because of the potential for myeloid toxicity. This study examined use patterns of 
pegﬁ lgrastim in real-life practice. METHODS: Analysis of health insurance claims
data in 2000–2007 from 35 large health plans across the US was conducted. Patients 
who had a cancer diagnosis and chemotherapy within 120 days of their ﬁ rst pegﬁ l-
grastim injection were identiﬁ ed. The proportion of pegﬁ lgrastim injections that were
followed by administration of chemotherapy within 11 and 9 days was calculated.
Analysis was also stratiﬁ ed by cancer type [Non-Hodgkin’s lymphoma (NHL), lung, 
and breast]. RESULTS: A total of 13,526 cancer patients received 57,118 pegﬁ lgrastim 
injections. NHL, lung, and breast cohorts comprised 2,722, 2,772, and 4,955 patients, 
respectively. Mean age (SD) was 55.0 (11.6) and women represented 65.9% of study
population. Among all cancer types, 19.2% of pegﬁ lgrastim injections had a chemo-
therapy claim within the following 11 days. This pattern of use was the highest in 
NHL (18.9%), followed by lung (17.1%), and breast (16.2%). Similar results were 
observed in the 9-day sensitivity analysis (all cancer: 16.2%, NHL: 17.4%, lung: 
16.0%, breast: 14.7%). CONCLUSIONS: Based on the retrospective analysis of this 
administrative claims database, the use of pegﬁ lgrastim within 11 days of an admin-
istration of chemotherapy was observed in 15–20% of cases which is inconsistent with
the recommended guidelines. Pegﬁ lgrastim use in these situations may have the poten-
tial to increase sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy.
Further research is being conducted to assess the related clinical and economic impact 
of this pattern of usage.
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PODIUM SESSION I: PERSONALIZED MEDICINE
PM1
PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT
Meckley LM, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: Personalized medicine (PM) has attracted tremendous interest, but 
yielded few marketed products. We examined factors inﬂ uencing the approval, cover-
age, and reimbursement of existing PM technologies. METHODS: We conducted six 
case studies of paired genetic tests and treatments in order to develop a framework 
to explain differences in adoption and reimbursement. We divided these case studies 
into three groups based on the purpose of the PM technology: Disease differentiation 
(HER2/neu with Herceptin (trastuzumab), hepatitis C genotyping with ribavirin/
pegylated interferon, and Oncotype DX with chemotherapy); pharmacogenetics
(UGT1A1 with irinotecan (Camptosar) and VKORC1/CYP2C9 with warfarin) and 
predisposition tests (BRCA 1/2 with prophylactic surgical measures and Oncotype DX
with chemotherapy). RESULTS: The factors inﬂ uencing approval, coverage and reim-
bursement appear based broadly on the purpose of, and evidence for, the PM technol-
ogy, rather than the type of device regulation (i.e., PMA, CLIA or 510(k)). Disease
differentiation test reimbursement is more widespread than other PM tests because 
of better evidence, guidelines, and clinician preferences. Predisposition tests may be 
reimbursed, despite the lack of randomized clinical trials, because people may value
the information from testing, regardless of the clinical consequences. Pharmacogenet-
ics (PGx) faces reimbursement hurdles because of the lack of evidence about clinical 
utility, though some companies bypass payers, and market PGx tests directly to con-
sumers. An additional challenge for all PM is the cumbersome existing coding system 
for reimbursement and the lack of value-based arrangements. CONCLUSIONS: To 
date, the promise and hype of PM has outpaced its evidentiary support. In order to
achieve favorable coverage and reimbursement and to support premium prices for
PM, manufacturers will need to bring better clinical evidence to the marketplace 
and develop better support for the value of their products. More ﬂ exible reim-
bursement systems are needed to reward PM technologies that demonstrate evidence
of value.
PM2
IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING
ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS
Hughes DA1, Al-Zubiedi S2, Hanson A2, Jorgensen A2, Pirmohamed M2
1Bangor University, Bangor, UK, 2University of Liverpool, Liverpool, UK
OBJECTIVES: The anticoagulant effect of warfarin is subject to wide dose variability
that may lead to hemorrhagic and thrombotic events. Variations in the CYP2C9 and 
VKORC1 genes together with clinical factors explain approximately 50% of this 
variability. The aim was to estimate the health care resource use, and overall costs
associated with therapy from the perspective of the UK NHS. METHODS: As part 
of a 6-month prospective cohort study evaluating pharmacogenetic and clinical factors 
associated with warfarin therapy, patients’ use of resources were recorded and costs
valued (UK a for 2006/7). Resource use was compared among patient sub-groups
(deﬁ ned by age; gender; CYP2C9 genotype; VKORC1 genotype; adverse events; co-
medication; co-morbidities; and smoking status). Mean costs were calculated with
95%CI estimated using non-parametric bootstrap sampling. RESULTS: Complete 
data were available for 254 patients. During the study period a total of 930 antico-
agulation visits (median 3 per patient, IQR 1, 5) and 4059 INR measurements (median 
15, IQR 10, 20) were recorded. Of the 70 patients who had experienced an adverse 
event, 16 (6.3%) required hospitalisation. Controlling for age, gender, and co-morbidi-
ties in patients who experienced an adverse event, the OR for hospitalization was 8.35 
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(95%CI 1.44, 48.35) for patients with the VKORC1 TT (rs9923231) genotype com-
pared with other genotypes. The mean cost of health care attributable to warfarin 
therapy was a392. The management of warfarin-related adverse events contributed to 
53% of the overall cost. The mean costs for those who experienced an adverse event 
was a884 (95%CI, 554, 1837) compared with a178 (95%CI, 164, 192) for the 179 
patients who did not. CONCLUSIONS: Our analysis is the ﬁ rst to demonstrate a 
signiﬁ cant association between VKORC1 variant genotype and hospitalization.
Although no independent effect on total cost was evident, carriers of VKORC1 TT 
were eight times more likely to be hospitalized due to adverse events.
PM3
USE OF PHARMACOGENETIC TESTING TO DETERMINE ADJUVANT
HORMONAL THERAPY CHOICE IN EARLY STAGE BREAST CANCER
PATIENTS: A VALUE OF INFORMATION ANALYSIS
Woods BS, Hawkins NS
Oxford Outcomes (UK), Oxford, UK
OBJECTIVES: To estimate the uncertainty regarding adjuvant treatment selection for 
postmenopausal women with early stage oestrogen-receptor positive breast cancer 
when pre-treatment CYP2D6 pharmacogenetic testing is considered as an option. In
addition, the expected value of partial perfect information (EVPPI) was estimated for 
different parameter sets to inform research prioritisation. METHODS: A decision 
analytic model estimated lifetime costs and quality adjusted life years (QALYs) for
four comparators: 5 years of tamoxifen; 5 years of an aromatase inhibitor (AI);
CYP2D6 test and treat wt/wt genotypes with tamoxifen and other genotypes with an 
AI; CYP2D6 test and treat wt/wt and wt/*4 genotypes with tamoxifen and *4/*4 
genotypes with an AI. No trial data for CYP2D6 contingent treatment pathways were 
identiﬁ ed. Trial data comparing tamoxifen to anastrozole was therefore synthesised 
with observational data linking CYP2D6 genotype to recurrence in patients receiving
tamoxifen. Estimates of the EVPPI were derived by attaching distributions to input
parameters and using two-level Monte Carlo simulation. EVPPI estimates were gener-
ated for parameters describing the efﬁ cacy of tamoxifen and anastrozole; parameters 
describing genotype-speciﬁ c tamoxifen efﬁ cacy; genotype prevalence; utility weights
and health state costs. RESULTS: The strategy of CYP2D6 test and treat wt/wt
patients with tamoxifen and all others with an AI maximised expected net beneﬁ t 
assuming a decision threshold of a30,000/QALY, and had an incremental cost-effec-
tiveness ratio of a14,133/QALY. However, this maximised net beneﬁ t with only 61% 
certainty. This substantial decision uncertainty led to an expected value of perfect
information estimate of a84 million. The EVPPI estimate for parameters describing 
genotype-speciﬁ c tamoxifen efﬁ cacy was a57 million. Estimates for other parameter
groups were low. CONCLUSIONS: Further CYP2D6 genotyping studies amongst
patients receiving tamoxifen should be prioritised. Expected value of sample informa-
tion analysis could be used to establish the cost-effectiveness and optimal design of 
this primary research.
PM4
AN EXPLORATION OF THE POTENTIAL CLINICAL BENEFITS
AND RISKS OF CYP2D6 TESTING TO GUIDE TAMOXIFEN THERAPY
IN BREAST CANCER
Veenstra DL, Lin MP, Garrison LP, Burke W
University of Washington, Seattle, WA, USA
OBJECTIVES: Recent studies have reported that women receiving adjuvant tamoxifen
with CYP2D6 poor metabolizer genotype have a higher risk of breast cancer recur-
rence than women without poor metabolizer genotype. The objective of this study 
was to evaluate pharmacogenetic testing for CYP2D6 variants as an approach to help 
clinicians identify postmenopausal women that would be better candidates for alterna-
tive therapies. METHODS: We developed a decision-analytic lifetime Markov model 
consisting of 6 health states and assessed a hypothetical cohort of 64-year old women
with ER breast cancer receiving tamoxifen. We assumed women who were poor
metabolizers would be switched to anastrazole. The incidence of local regional relapse, 
metastasis, and breast cancer death were obtained from the 2005 ATAC trial. The 
hazard ratio for disease recurrence in poor vs. extensive metabolizers was derived from 
a recent study by Goetz et al. Cost, utilities and background mortality rates were 
obtained from the published literature or publicly available sources. One-way sensitiv-
ity analyses and scenario analyses were conducted to evaluate uncertainty. RESULTS:
Projected disease free survival at 5 years was 81.4% for tamoxifen and 83.3% for
anastrozole, compared to 81.0% and 83.8% in the ATAC trial. Treatment with
tamoxifen resulted in 11.95 QALYs, anastrozole 12.15 QALYs, and CYP2D6-guided 
treatment 12.19 QALYs. The testing strategy resulted in the greatest QALYs with a 
hazard ratio for recurrence in CYP2D6 variant versus wild-type patients of 1.66 or 
higher, or variant prevalence greater than 20%. CONCLUSIONS: Genetic testing for 
CYP2D6 status in postmenopausal women taking adjuvant tamoxifen may lead to 
clinically meaningful improvements in survival and quality of life. Evaluation of the 
relative impact of drug-related adverse events, validation of association studies, and
assessment in ethnically diverse populations are needed before widespread testing can 
be recommended.
PODIUM SESSION I: RESEARCH ON METHODS – Utility Methods
UT1
ON THE ISSUE OF UTILITY MULTIPLICATION: A REVISIT
Fu AZ
Cleveland Clinic, Cleveland, OH, USA
OBJECTIVE: Several estimators exist when average utility scores are not available for
patient populations with multiple disease conditions. The multiplicative estimator is 
a widespread choice among them. This study is to empirically test the accuracy of the
multiplicative estimator and compare it with other estimators. METHODS: Using the
pooled Medical Expenditure Panel Survey (MEPS) 2001 and 2003 data, a sample of 
40,846 adults with EQ-5D preference-based index scores were categorized into 238
disease condition categories. Due to the MEPS sampling property, co-morbid pair 
categories with less than 100 individuals were excluded, which left us with 760 co-
morbid pairs in total. The study focus was the bias from the estimators to the observed 
mean scores for each co-morbid pair, with the observed scores presumed to be the 
true value. The analyses were conducted using both the raw estimators and the res-
caled (puriﬁ ed) estimators. Regressions and concordance correlation coefﬁ cients were 
also used to evaluate the agreement between the estimators and the observed scores.
RESULTS: Using the rescaled approach, the scores estimated by multiplying the 2
mean scores of the corresponding disease conditions on average had a statistically 
signiﬁ cantly larger bias (p  0.0001) from the observed ones (0.043) than simply 
picking the smaller mean of the 2 paired conditions (minimum estimator, bias  0.027). 
However, the multiplicative estimator had less bias than other estimators including 
the additive estimator (bias  0.054), the larger mean (bias  0.077), the average of 
the means (bias  0.052), mean of the condition with smaller sample (bias  0.053). 
Results produced by other analyses, including using the raw scores, all favored the 
minimum estimator than the multiplicative estimator. CONCLUSIONS: Multiplica-
tion is not a good estimate when the average utility score for patients with 2 disease
conditions is not readily available. The lower of the 2 utility scores had the least error 
among those estimators that we compared.
UT2
ELICITING TIME TRADE-OFF AMOUNTS FOR HEALTH STATES IN
HYPOTHETICAL INDIVIDUALS OF DIFFERENT AGES USING A 
DISCRETE CHOICE EXPERIMENT
Prosser LA1, Rusinak D2, Payne K3, Shi P2, Uyeki TM4, Messonnier M4
1University of Michigan, Ann Arbor, MI, USA, 2Harvard Pilgrim Health Care and Harvard 
Medical School, Boston, MA, USA, 3University of Manchester, Manchester, UK, 4Centers for 
Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVE: To measure whether public values for health vary with the age of the
affected individual. METHODS: We ﬁ elded a discrete choice experiment via the
internet in December 2007 to measure preferences for different attributes of inﬂ uenza-
related health states: length of episode (days of illness), severity of illness (workdays
lost), age of hypothetical affected individual (range: 1–85 yrs), and time-tradeoff 
amounts (1day – 2 yrs). We also collected data on socio-demographic characteristics 
and experience with inﬂ uenza illness. Respondents were 18 years and older and
matched to reﬂ ect characteristics of the general US adult population (n  1012). 
Response rate was 67%. Respondents were presented with pairs of illness proﬁ les for
a hypothetical individual and indicated the proﬁ le they preferred. Each respondent
answered 8 discrete choice questions. A full factorial design was used. Discrete choice
analysis using generalized estimating equations was used to evaluate the relative value
of different attributes in the illness proﬁ le while controlling for socio-demographic 
characteristics and inﬂ uenza experience. RESULTS: As measured by time-tradeoff 
amounts, respondents preferred shorter inﬂ uenza episodes (total length) but did not
signiﬁ cantly prefer fewer workdays lost if episode length was held constant. Respon-
dents preferred to avert uncomplicated illness in very young children (1 year old child:
odds ratio  2.35, p  0.05; 3 year old child: odds ratio  3.21, p  0.01) and older
adults (85 year old: odds ratio  2.41, p  0.05) compared to a 35 year old adult. For 
an inﬂ uenza-related hospitalization, respondents preferred to avert illness in very 
young children (1 year old child: odds ratio  2.86, p  0.01) compared to a 35 year 
old adult. CONCLUSIONS: Approaches that assume values for illnesses do not vary
with the age of a patient may bias economic analyses that use these values. If patient
age is likely to affect valuations, then age should be included as an attribute in the
valuation exercise.
UT3
THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, 
PROGNOSIS AND QUALITY OF LIFE
van Hout BA
Pharmerit Ltd, York, North Yorkshire, UK
OBJECTIVE: Do people weigh gains in life years differently when patients differ in 
age (but not in life expectancy), life expectancy (but not in age) or QOL (but not age 
or life expectancy)? METHODS: Trade off questions wer developed searching for
indifference between giving healthy life years to patients with different ages, prognoses 
and quality of life. Data come from 46 heart failure patients, 60 healthy controls and 
180 students. For age, as well as prognosis and QOL, six comparative sets were 
developed. Each respondent answered two questions of each set and two combina-
tion-questions. Ordered logistic regression was used in combination with conditional 
linear regression for “extreme” answers. Answers are “extreme” when, for example, 
one extra life year in a young patient is preferred to 10 in an old patient or when
respondents can’t choose. RESULTS: More than 40% of the answers are “extreme”.
